[Federal Register Volume 64, Number 42 (Thursday, March 4, 1999)] [Notices] [Pages 10512-10515] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 99-5374] ----------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION [Release No. 34-41100; File No. SR-Amex-98-31] Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change and Amendment Nos. 1 and 2 by the American Stock Exchange LLC Relating to Options on the Cure for Cancer Common Stock Index February 24, 1999. Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 (``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby give that on August 14, 1998, the American Stock Exchange LLC (``Amex'' or ``Exchange'') filed with the Securities and Exchange Commission (``Commission '') the proposed rule change. The Exchange submitted Amendment No. 1 to its proposal on January 28, 1999,\3\ and Amendment No. 2 on February 24, 1999.\4\ The proposed rule change, as amended, is described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons. --------------------------------------------------------------------------- \1\ 15 U.S.C. 78s(b)(1). \2\ 17 CFR 240.19b-4. \3\ In Amendment No. 1, the Exchange amended its eligibility standard for component securities by adding an additional level of trading volume. Further, the Exchange amended its maintenance criteria by raising the percentage of the index that must satisfy Rule 915, clarifying that the Commission has agreed to a specific component of the index satisfying the standard set forth in Amex Rule 916 instead of Amex Rule 915, and specifying that 90% of the weight of the index must have a minimum monthly trading volume of 500,000 shares and 10% of the weight of the index must have a minimum trading volume of 350,000 shares for each of the last six months. See Amended Rule 19b-4 Filing (``Amendment No. 1''). \4\ In Amendment No. 2, the Exchange specified its procedure for rebalancing the index in the event of certain types of corporate events, raised its eligibility standard for component securities by raising the level of trading volume required for initial eligibility, clarified that Cell Pathways, Inc. currently satisfies the initial options eligibility criteria of Amex Rule 915, and clarified that the Exchange will maintain the index consistent with its original purpose. Further, the Exchange specified that stock replacements and the handling of non-routine corporate actions will be announced at least ten business days in advance whenever possible. See Letter from Scott Van Hatten, Legal Counsel, Amex, to Richard Strasser, Assistant Director, Division of Market Regulation (``Division''), Commission, dated February 23, 1999 (``Amendment No. 2''). --------------------------------------------------------------------------- I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change The Exchange proposes to trade options on the Cure for Cancer Common Stock Index (``Index''), a new index [[Page 10513]] developed by Amex comprising of companies engaged in the research, creation, development and production of cancer fighting drugs, treatments and processes. II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change In its filing with the Commission, Amex included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. Amex has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements. A. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change 1. Purpose The purpose of the proposed rule change is to permit the Exchange to trade standardized options on the Index. The Index is composed of the stocks of twelve companies engaged in the research, creation, development and production of cancer fighting drugs, treatments and processes. Options on the Index will provide investors with a low-cost means to participate in the performance of the cancer research, treatment and cure industry and to hedge against the risk of investing in the industry. Eligibility Standards for Index Components Amex, as developer of the Index, is responsible for selecting and maintaining the companies to be included in the Index. The Index conforms with the criteria of Exchange Rule 901C for including stocks in an index on which standardized options trade. In addition, all of the component securities currently meet the following standard: (1) each component has a market capitalization of at least $75 million, except one that has a market value of at least $50 million and accounts for no more than 10% of the weight of the Index; (2) more than 80% of the weight of the Index is accounted for by securities each having a trading volume of not less than 1,000,000 shares over each of the six months and the remaining 20% of the weight of the Index is accounted for by one component having a trading volume of not less than 850,000 shares and the other, specifically agreed to by the Commission, trading not less than 350,000 shares over each of the six months,\5\ (3) 75% of the Index's components and its numerical index value currently underlie standardized options; (4) foreign country securities or American Depositary Receipts (``ADR'') thereon are not currently represented in the Index; (5) all component stocks are either listed on the New York Stock Exchange (``NYSE''), Amex, or traded through the facilities of the National Association of Securities Dealers Automated Quotation System (``Nasdaq'') and are reported National Market System (``NMS'') securities; and (6) no component security represents more than 25% of the weight of the Index, and the five highest weighted component securities in the Index do not in the aggregate account for more than 60% of the weight of the Index. --------------------------------------------------------------------------- \5\ See Amendment No. 1, supra note 3 and Amendment No.2, supra note 4. The Amex represents that it will verify that the individual component securities satisfy this requirement as of February 26, 1999. Telephone conversation between Scott Van Hatten, Legal Counsel, Amex, and Terri Evans, Attorney, Division, Commission, on February 23, 1999. --------------------------------------------------------------------------- The Exchange believes the potential for manipulation of the Index is minimized for the following reasons: (1) no single component dominates the Index, which is equal-dollar weighted, with each component constituting approximately 8.3% of the Index; (2) 75% of the value of the Index is accounted for by stocks which currently underlie standardized options; and (3) the component stocks are substantial and liquid, having an average market capitalization of $247.43 million, an average of 22.39 million shares outstanding, and a six-month average monthly trading volume of 4.9 million shares. Index Maintenance The Index will be maintained by the Exchange consistent with its original purpose (i.e., to include components engaged in the research, creation, development and production of cancer fighting drugs, treatments and processes).\6\ The number of shares of each component stock in the Index portfolio will remain fixed between quarterly rebalances except in the event of certain types of corporate actions.\7\ If necessary in order to maintain continuity of the Index, its divisor may be adjusted to reflect certain events relating to the component stocks. These events include, but are not limited to, stock distributions, stock splits, reverse stock splits, spin-offs, certain rights issuance, recapitalizations, reorganizations, and mergers and acquisitions. All stock replacements and the handling of non-routine corporate actions will be announced at least ten business days in advance of such effective change, whenever possible. The Exchange will make this information available to the public through dissemination of an information circular.\8\ --------------------------------------------------------------------------- \6\ See Amendment No. 2, supra note 4. \7\ Id. \8\ Id. --------------------------------------------------------------------------- The Exchange will maintain the Index so that (1) the Index is comprised of no less than nine component securities; (2) the component securities constituting the top 90% of the Index by weight, will have a minimum market capitalization of $75 million and the component stocks constituting the bottom 10% of the Index, by weight, may have a minimum market capitalization of $50 million; (3) 75% of the Index's numerical index value will meet the then current criteria for standardized option trading set forth in Amex Rule 915, except that one component included in the 75% and specifically agreed to by the Commission may meet the then current criteria set forth in Amex Rule 916,\9\ (4) foreign country securities or ADRs thereon that are not subject to comprehensive surveillance agreements will not in the aggregate represent more than 20% of the weight of the Index; (5) all component stocks will either be listed on Amex, NYSE, or Nasdaq/NMS; and (6) each of the component stocks shall have a minimum monthly trading volume of at least 500,000 shares for each of the last six months, except that for each of the lowest weighted components in the Index that in the aggregate account for no more than 10% of the weight of the Index, trading volume must be at least 350,000 shares for each of the last six months.\10\ --------------------------------------------------------------------------- \9\ See Amendment No. 1, supra note 3. \10\ Id. --------------------------------------------------------------------------- The Exchange shall not open for trading any additional option series should the Index fail to satisfy any of the maintenance criteria set forth above unless such failure is determined by the Exchange not to be significant and the Commission concurs in that determination. Index Calculation The Index will be calculated by the Amex using an ``equal-dollar weighted'' methodology. The following is a description of the methodology. As of the market close on December 31, 1992, a portfolio of stocks was established representing an investment of approximately $100,000 in the stock (rounded to the nearest whole share) of [[Page 10514]] each of the companies in the index. The value of the Index equals the current market value (i.e., based on U.S. primary market prices) of the sum of the assigned number of shares of each of the stocks in the Index portfolio divided by the Index divisor. The Index divisor was initially determined to yield the benchmark value of 100.00 as of the close of trading on December 31, 1992. Quarterly, following the close of trading on the third Friday of February, May, August and November, the Index portfolio will be adjusted by changing the number of whole shares of each component stock so that each company is again represented in ``equal'' dollar amounts. If necessary, a divisor adjustment is made during the rebalancing to ensure continuity of the Index's value. The newly adjusted portfolio becomes the basis for the Index's value on the first trading day following the quarterly adjustment. As noted above, the number of shares of each component stock in the Index portfolio remain fixed between quarterly reviews except in the event of certain types of corporate actions such as the payment of a dividend other than an ordinary cash dividend, stock distribution, reorganization, recapitalization, or similar event with respect to the component stocks. In a merger or consolidation of an issuer of a component stock, if the stock remains in the Index, the number of shares of that security of the portfolio may be adjusted, to the nearest whole share, to maintain the component's relative weight in the Index at the level immediately prior to the corporate action. In the event of a stock addition to a replacement, the average dollar value of the remaining components will be calculated and that amount invested in the stock of the new component to the nearest whole share. In all cases, the divisor will be adjusted, if necessary, to ensure Index continuity. Similar to other stock index values published by the Exchange, the value of the Index will be calculated continuously and disseminated every 15 seconds over the Consolidated Tape Association's Network B. Expiration and Settlement The proposed options on the Index will be European style (i.e., exercises permitted at expiration only) and cash settled. Standard option trading hours (9:30 a.m. to 4:02 p.m. (ET)) will apply. The options on the Index will expire on the Saturday following the third Friday of the expiration month. The last trading day in an expiring option series will normally be the second to last business day preceding the Saturday following the third Friday of the expiration month (normally a Thursday). Trading in expiring options will cease at the close of trading on the last trading day. The Exchange plans to list option series with expirations in the three near-term calendar months and in the two additional calendar months in the March cycle. In addition, longer-term option series having up to thirty-six months to expiration and FLEX Index options may be traded on the Index. Instead of such long-term options on a full value Index level, the Exchange may list long-term, reduced value put and call options based on one-tenth (\1/10\th) of the Index's full value. The interval between expirations months for either a full value or reduced value long-term option will not be less than six months. The trading of any long-term options, either full or reduced value, would be subject to the same rules that govern the trading of all the Exchange's index options, including sales practice rules, margin requirements and floor trading procedures, and all options will have Europeans style exercise. The exercise settlement value for all of the Index's expiring options will be calculated based upon the primary exchange regular way opening sale prices for the component stocks. In the case of securities traded through the Nasdaq system, the first reported regular way sale price will be used. If any component stock does not open for trading on its primary market on the last trading day before expiration, then the prior day's last sale price will be used in the calculation.\11\ --------------------------------------------------------------------------- \11\ The Commission notes that pursuant to Article XVII, Section 4 of the Options Clearing Corporation's (``OCC'') by-laws, OCC is empowered to fix an exercise settlement amount in the event it determines a current index value is unreported or otherwise unavailable. Further, OCC has the authority to fix an exercise settlement amount whenever the primary market for the securities representing a substantial part of the value of an underlying index is not open for trading at the time when the current index value (i.e., the value used for exercise settlement purposes) ordinarily would be determined. See Securities Exchange Act Release No. 37315 (June 17, 1996), 61 FR 42671 (order approving SR-OCC-95-19). --------------------------------------------------------------------------- Exchange Rules Applicable to Stock Index Options Amex Rules 900C through 980C will apply to the trading of option contracts based on the Index. These Exchange Rules cover issues such as surveillance, exercise prices and position limits. The Index is deemed to be a Stock Index Option under Amex Rule 901C(a) and a Stock Index Industry Group under Amex Rule 900C(b)(1). With respect to Amex Rule 903C(b), the Exchange proposes a list near-the-money (i.e., within ten points above or below the current Index value) option series on the Index at 2\1/2\ point strike (exercise) price intervals when the value of the Index is below 200 points. In addition, the Exchange expects that the review required by Amex Rule 904C(c) will result in a position limit of 15,000 contracts with respect to options on this Index. Surveillance procedures currently used to monitor trading in each of the Exchange's other index options will also be used to monitor trading options on the Index. 2. Statutory Basis The proposed rule change is consistent with Section 6(b) of the Act \12\ in general and furthers the objectives of Section 6(b)(5) \13\ in particular in that it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, and is not designed to permit unfair discrimination between customers, issuers, brokers or dealers. --------------------------------------------------------------------------- \12\ 15 U.S.C. 78f(b). \13\ 15 U.S.C. 78f(b)(5). --------------------------------------------------------------------------- B. Self-Regulatory Organization's Statement on Burden on Competition The proposed rule change will impose no burden on competition. C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others The Exchange has neither solicited nor received written comments with respect to the proposed rule change. III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the Amex consents, the Commission will: (A) By order approve such proposed rule change, or (B) Institute proceedings to determine whether the proposed rule change should be disapproved. IV. Solicitation of Comments Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange [[Page 10515]] Commission, 450 Fifth Street, NW, Washington, DC 20549. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room in Washington, DC. Copies of such filing will also be available for inspection and copying at the principal office of the Exchange. All submissions should refer to File No. SR-Amex-98-31 and should be submitted by March 25, 1999. For the Commission, by the Division of Market Regulation, pursuant to delegated authority.\14\ --------------------------------------------------------------------------- \14\ 17 CFR 200.30-3(a)(12). --------------------------------------------------------------------------- Margaret H. McFarland, Deputy Secretary. [FR Doc. 99-5374 Filed 3-3-99; 8:45 am] BILLING CODE 8010-01-M
Document
Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change and Amendment Nos. 1 and 2 by the American Stock Exchange LLC Relating to Options on the Cure for Cancer Common Stock Index
[Federal Register Volume 64, Number 42 (Thursday, March 4, 1999)] [Notices] [Pages 10512-10515] From the Federal Register Online via the Government Publishing Office [ www.gpo.g...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
64 FR 10512
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change and Amendment Nos. 1 and 2 by the American Stock Exchange LLC Relating to Options on the Cure for Cancer Common Stock Index,” thefederalregister.org (March 4, 1999), https://thefederalregister.org/documents/99-5374/self-regulatory-organizations-notice-of-filing-of-proposed-rule-change-and-amendment-nos-1-and-2-by-the-american-stock-e.